|
|
|
| Experience summary of Professor An Haiyan in treating diabetic nephropathy with “xinrun tongluo method” |
| ZHAO Jing1 AN Haiyan2 CAO Yunsong2 GUO Xiaoyuan2#br# |
1.The Second Clinical School, Beijing University of Chinese Medicine, Beijing 100029, China;
2.Department of Nephrology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China |
|
|
|
Abstract Diabetic nephropathy is the major microvascular complication of diabetes, and it is also the main cause of end-stage renal disease, the treatment is difficult. Professor An Haiyan believes that the disease always belongs to the syndrome of “deficiency of root cause and excess of manifestation”, and emphasizes that “blood stasis of kidney collaterals” is the core pathogenesis of the disease, which runs through the whole process. Pay attention to treatment by stages, give consideration to both manifestation and root cause, and develop both deficiency and excess. When the prescription is used, it should be flexibly combined with “xintong” and “rourun” Chinese medicine, and “xinrun tongluo method” should be skillfully used in the treatment of each stage, which should be determined according to the syndrome. Each clinical certificate is validated. This article summarizes and discusses Professor An Haiyan’s experience in treating diabetic nephropathy, and attaches a case of medical treatment to prove it, so as to broaden the train of thought for clinical treatment of this disease.
|
|
|
|
|
|
[1] Zhang L，Long J，Jiang W，et al. Trends in chronic kidney disease in China [J]. N Engl J Med，2016，375（9）：905-906.
[2] American Diabetes Association. 11.Microvascular complications and foot care：Standards of Medical Care in Diabetes-2020 [J]. Diabetes Care，2020，43 Suppl 1：S135-S151.
[3] Umanath K，Lewis JB. Update on diabetic nephropathy：core curriculum 2018 [J]. Am J Kidney Dis，2018，71（6）：884-895.
[4] KDIGO. 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease [J]. Kidney Int Suppl，2013，3（1）：1-150.
[5] Meng X，Wei MM，Wang D，et al. Astragalus polysaccharides protect renal function and affect the TGF-β/Smad signaling pathway in streptozotocin-induced diabetic rats [J].J Int Med Res，2020，48（5）：300060520903612．
[6] Park CH，Hiratani K，Natazuka T，et al. Therapeutic effect of Chinese prescription Kangen-karyu in patients with diabetic nephropathy [J]. Drug Discov Ther，2020，14（2）：84-88．
[7] Huang WJ，Liu WJ，Xiao YH，et al. Tripterygium and its extracts for diabetic nephropathy：efficacy and pharmacological mechanisms [J]. Biomedecine Pharmacother，2020， 121：109599．
[8] Sohn E，Kim J，Kim CS，et al. Extract of Rhizoma Polygonum cuspidatum reduces early renal podocyte injury in streptozotocin-induced diabetic rats and its active compound emodin inhibits methylglyoxal-mediated glycation of proteins [J]. Mol Med Rep，2015，12（4）：5837-5845．
[9] 高彦彬，刘铜华，李平.糖尿病肾病中医防治指南[J].中国中医药现代远程教育，2011，9（4）：151-153.
[10] 甄立言，范行准，梁峻.古今录验方[M].北京：中医古籍出版社，2019：142.
[11] 姚洁琼，高艳霞，王耀献，等.肾络癥瘕理论分期治疗糖尿病肾病验案[J].中国临床医生杂志，2019，47（1）：121-123.
[12] 陈亮，丁英钧.赵玉庸治疗糖尿病肾病经验[J].中华中医药杂志，2020，35（1）：244-247.
[13] 王兴，林燕.曹式丽从络论治糖尿病肾病学术经验初探[J].中国中西医结合肾病杂志，2017，18（11）：993-994.
[14] 戴恩来.慢性肾脏病“毒损肾络”病机概论[J].中国中西医结合肾病杂志，2014，15（2）：97-100.
[15] 胡筱娟，秦燕，刘恬园.基于肾络瘀阻病机与糖尿病肾病相关性临床研究[J].陕西中医，2015，36（12）：1614-1616.
[16] 王清任.医林改错[M].北京：人民军医出版社，2007：53.
[17] 宋彦，贾新华，张心月，等.从“辛润通络法”论治干燥综合征合并间质性肺疾病[J].河北中医药学报，2021，36（4）：22-25.
[18] 宋锦华，王彤，刘秀萍.浅谈糖尿病肾病水肿的治疗[J].环球中医药，2019，12（7）：1067-1070.
[19] 闫润泽，孙卫卫，王耀献，等.王耀献教授辨期论治糖尿病肾病[J].中国中西医结合肾病杂志，2020，21（9）：753-755.
[20] 林敏，鲁玉辉.“临证指南医案”辛润通络法探骊[J].中华中医药杂志，2018，33（6）：2267-2269.
[21] 杜茜蕾，王雪茜.从叶氏辛润通络法看其对仲景旋覆花汤的继承与发展[J].环球中医药，2019，12（5）：729-731.
[22] 杨波，周扬.基于“辛以润之”理论的辛味中药研究初探[J].中国中医药现代远程教育，2009，7（6）：7-8.
[23] 陈俊利，杨康，杨洪涛，等.藤类药在慢性肾脏病中的应用现状[J].中国中西医结合肾病杂志，2021，22（6）：550-553.
[24] 王娅辉，杨蕊冰，郭科婷，等.刘玉宁教授治疗慢性肾脏疾病经验集萃[J].中国中西医结合肾病杂志，2020，21（11）：941-942.
[25] 张思超.《温病条辨》芳香药钩玄及临床运用[J].山东中医杂志，2019，38（10）：903-906.
[26] 田永林，龚婕宁.叶天士应用虫类药经验探析[J].新中医，2019，51（10）：317-319. |
|
|
|
